Asia-Pacific Vaccines Market - Industry Trends and Forecast to 2030

Description

List of Tables

Asia-Pacific vaccines market is projected to register a CAGR of 9.4% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2023 to 2030.

Market Segmentation:

Asia-Pacific Vaccines Market, By Composition (Combination Vaccines and Mono Vaccines), Type (Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines, Live-Attenuated Vaccines, Inactivated Vaccines, and Toxoid Vaccines), Kind (Routine Vaccine, Recommended Vaccine, and Required Vaccine), Age of Administration (Pediatric Vaccine and Adult Vaccine), Diseases (Pneumococcal Disease, Measles, Mumps & Varicella, DPT, Hepatitis, Influenza, Typhoid, Meningococcal, Rabies, Japanese Encephalitis, Yellow Fever, and Others), Route of Administration (Injectable, Oral, and Nasal), End User (Community Hospitals, Hospitals, Specialty Centres, Clinics, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), Country (Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam, and Rest of Asia-Pacific) Industry Trends and Forecast to 2030

Some of the major factors contributing to the growth of the vaccines market are:

Growing immunization programs and campaigns

Improvement in treatment

Launch of newer vaccines

Market Players:

The key market players for Asia-Pacific vaccines market are listed below:

Abbott

ALK

AstraZeneca

BAXTER VACCINES (A Subsidiary of Baxter)

Bharat Biotech

Bio Farma

Biological E Limited

DAIICHI SANKYO COMPANY, LIMITED

F. Hoffmann-La Roche Ltd

GlaxoSmithKline plc.

Janssen Global Services, LLC (A Subsidiary of Johnson & Johnson Services, Inc.)

Lanzhou Biological Products Research Institute Co., Ltd.

Merck sharp & Dohme corp. (A Subsidiary of Merck & Co., Inc.)

Panacea Biotec Ltd

Pfizer Inc.

Sanofi

Seqirus (A Subsidiary of CSL Limited)

Serum Institute of India Pvt. Ltd.

Takeda Pharmaceutical Company Limited

1 INTRODUCTION 24

1.1 OBJECTIVES OF THE STUDY 24
1.2 MARKET DEFINITION 24
1.3 OVERVIEW OF THE ASIA-PACIFIC VACCINES MARKET 24
1.4 LIMITATIONS 27
1.5 MARKETS COVERED 27

2 MARKET SEGMENTATION 30

2.1 MARKETS COVERED 30
2.2 GEOGRAPHICAL SCOPE 31
2.3 YEARS CONSIDERED FOR THE STUDY 31
2.4 CURRENCY AND PRICING 31
2.5 DBMR TRIPOD DATA VALIDATION MODEL 32
2.6 MULTIVARIATE MODELLING 35
2.7 COMPOSITION LIFELINE CURVE 36
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 37
2.9 DBMR MARKET POSITION GRID 38
2.10 SECONDARY SOURCES 40
2.11 ASSUMPTIONS 40

3 EXECUTIVE SUMMARY 41

4 PREMIUM INSIGHT 45

4.1 PESTEL MODEL 45
4.2 PORTER'S FIVE FORCES 46
4.3 EPIDEMIOLOGY 47
4.4 INDUSTRIAL INSIGHTS: 48
4.5 PIPELINE ANALYSIS 50
4.6 ASIA-PACIFIC VACCINES MARKET: SUPPLY CHAIN MANAGEMENT OF VACCINES 55
- 4.6.1 COLD CHAIN STORAGE: 56
- 4.6.2 PROCESS OF LOGISTICS 58

5 REGULATORY FRAMEWORK 60

5.1 JAPAN 60
5.2 CHINA 61
5.3 SOUTH KOREA 61
5.4 INDIA 61
5.5 AUSTRALIA 62
5.6 SINGAPORE 63
5.7 THAILAND 64
5.8 MALAYSIA 64
5.9 INDONESIA 64
5.10 VIETNAM 65
5.11 PHILIPPINES 66
5.12 REST OF ASIA-PACIFIC 66
- 5.12.1 TAIWAN 67
- 5.12.2 CAMBODIA 68

6 MARKET OVERVIEW 69

6.1 DRIVERS 71
- 6.1.1 GROWING IMMUNIZATION PROGRAMS AND CAMPAIGNS 71
- 6.1.2 HIGH PREVALENCE OF CHRONIC CONDITIONS SUCH AS FLU, INFECTIOUS AND VIRAL DISEASES 71
- 6.1.3 IMPROVEMENT IN TREATMENT 72
- 6.1.4 LAUNCH OF NEWER VACCINES 72
- 6.1.5 INCREASING GOVERNMENT SUPPORT 73
6.2 RESTRAINTS 73
- 6.2.1 UNAVAILABILITY OF REGISTERED VACCINES 73
- 6.2.2 DIFFICULTIES ASSOCIATED WITH THE TRANSPORT AND PRODUCTION OF VACCINES 74
6.3 OPPORTUNITIES 74
- 6.3.1 STRATEGIC INITIATIVES BY THE MARKET PLAYERS 74
- 6.3.2 PRESENCE OF PIPELINE PRODUCTS 75
- 6.3.3 RISE IN EXPENDITURE IN THE HEALTHCARE SECTOR 76
- 6.3.4 INCREASING AWARENESS FOR VACCINATION 77
6.4 CHALLENGES 77
- 6.4.1 SIDE EFFECTS CAUSED BY VACCINES 77
- 6.4.2 FEAR AMONG PATIENTS RELATED TO INJECTIONS AND NEEDLE STICKS 78
- 6.4.3 PRODUCT RECALL 78

7 ASIA-PACIFIC VACCINES MARKET, BY COMPOSITION 80

7.1 OVERVIEW 81
7.2 COMBINATION VACCINES 84
7.3 MONO VACCINES 84

8 ASIA-PACIFIC VACCINES MARKET, BY TYPE 85

8.1 OVERVIEW 86
8.2 SUBUNIT, RECOMBINANT, POLYSACCHARIDE, AND CONJUGATE VACCINES 89
- 8.2.1 PNEUMOCOCCAL DISEASE 90
- 8.2.2 HIB (HAEMOPHILUS INFLUENZA TYPE B) DISEASE 90
- 8.2.3 HPV (HUMAN PAPILLOMA VIRUS) 90
- 8.2.4 HEPATITIS B 90
- 8.2.5 MENINGOCOCCAL 90
- 8.2.6 SHINGLES 90
- 8.2.7 WHOOPING COUGH 90
- 8.2.8 OTHERS 90
8.3 LIVE-ATTENUTAED VACCINES 90
- 8.3.1 ROTAVIRUS 91
- 8.3.2 MEASLES 91
- 8.3.3 MUMPS 91
- 8.3.4 RUBELLA 91
- 8.3.5 SMALLPOX 91
- 8.3.6 YELLOW FEVER 91
- 8.3.7 OTHERS 92
8.4 INACTIVATED VACCINES 92
- 8.4.1 FLU (SHOT ONLY) 92
- 8.4.2 POLIO (SHOT ONLY) 92
- 8.4.3 HEPATITIS A 93
- 8.4.4 RABIES 93
- 8.4.5 OTHERS 93
8.5 TOXOID VACCINES 93
- 8.5.1 DIPHTHERIA, TETANUS & PERTUSSIS (DTP) 94
- 8.5.2 OTHERS 94

9 ASIA-PACIFIC VACCINES MARKET, BY KIND 95

9.1 OVERVIEW 96
9.2 ROUTINE VACCINES 99
- 9.2.1 PNEUMOCOCCAL DISEASES 99
9.3 DIPTHERIA, TETANUS & PERTUSIS(DPT) 100
- 9.3.1 HIB (HAEMOPHILUS INFLUENZA TYPE B) DISEASE 100
- 9.3.2 MEASLES 100
- 9.3.3 MUMPS 100
- 9.3.4 HEPATITIS B 100
- 9.3.5 RUBELLA 100
- 9.3.6 POLIO 100
- 9.3.7 OTHERS 100
9.4 RECOMMENDED VACCINE 100
- 9.4.1 TYPHOID FEVER VACCINE 101
9.5 HEPATITIS A 101
- 9.5.1 RABIES 101
- 9.5.2 JAPANESE ENCEPHALITIS 101
- 9.5.3 TICK-BORNE ENCEPHALITIS 102
- 9.5.4 CHOLERA 102
- 9.5.5 OTHERS 102
9.6 REQUIRED VACCINE 102
- 9.6.1 MENINGOCOCCAL 103
9.7 YELLOW FEVER 103
- 9.7.1 OTHERS 103

10 ASIA-PACIFIC VACCINES MARKET, BY AGE OF ADMINISTRATION 104

10.1 OVERVIEW 105
10.2 PEDIATRIC VACCINE 108
- 10.2.1 PNEUMOCOCCAL DISEASES 109
10.3 MEASLES, MUMPS & RUBELLA 109
- 10.3.1 DIPTHERIA, TETANUS & PERTUSIS (DPT) 109
- 10.3.2 ROTAVIRUS 109
- 10.3.3 MENINGOCOCCAL 109
- 10.3.4 VARICELLA 109
- 10.3.5 POLIO 109
- 10.3.6 TUBERCULOSIS 109
- 10.3.7 MALARIA 109
- 10.3.8 OTHERS 109
10.4 ADULT VACCINE 110
- 10.4.1 INFLUENZA 111
10.5 HPV (HUMAN PAPILLOMA VIRUS) 111
- 10.5.1 TYPHOID 111
- 10.5.2 HEPATITIS B 111
- 10.5.3 JAPANESE ENCEPHALITIS 111
- 10.5.4 YELLOW FEVER 111
- 10.5.5 CANCER 111
- 10.5.6 OTHERS 111

11 ASIA-PACIFIC VACCINES MARKET, BY DISEASES 112

11.1 OVERVIEW 113
11.2 PNEUMOCCOCAL DISEASE 116
11.3 MEASLES, MUMPS & RUBELLA 116
11.4 DPT 117
11.5 HEPATITIS 117
11.6 INFLUENZA 117
11.7 TYPHOID 118
11.8 MENINGOCOCCAL 118
11.9 VARICELLA 119
11.10 RABIES 119
11.11 JAPANESE ENCEPHALITIS 119
11.12 YELLOW FEVER 120
11.13 OTHERS 120

12 ASIA-PACIFIC VACCINES MARKET, BY ROUTE OF ADMINISTRATION 121

12.1 OVERVIEW 122
12.2 INJECTABLE 125
- 12.2.1 INTRAMUSCULAR 125
- 12.2.2 SUBCUTANEOUS 125
- 12.2.3 INTRADERMAL 125
12.3 ORAL 126
12.4 NASAL 126

13 ASIA-PACIFIC VACCINES MARKET, BY END USER 127

13.1 OVERVIEW 128
13.2 COMMUNITY HOSPITALS 131
13.3 HOSPITALS 131
13.4 SPECIALTY CENTERS 131
13.5 CLINICS 132
13.6 OTHERS 132

14 ASIA-PACIFIC VACCINES MARKET, BY DISTRIBUTION CHANNEL 133

14.1 OVERVIEW 134
14.2 HOSPITAL PHARMACY 137
14.3 RETAIL PHARMACY 137
14.4 ONLINE PHARMACY 138

15 ASIA-PACIFIC VACCINE MARKET 139

15.1 ASIA-PACIFIC 139
- 15.1.1 JAPAN 144
- 15.1.2 CHINA 150
- 15.1.3 AUSTRALIA 156
- 15.1.4 INDIA 162
- 15.1.5 SOUTH KOREA 168
- 15.1.6 SINGAPORE 175
- 15.1.7 MALAYSIA 181
- 15.1.8 THAILAND 187
- 15.1.9 INDONESIA 193
- 15.1.10 PHILIPPINES 199
- 15.1.11 VIETNAM 205
- 15.1.12 REST OF ASIA PACIFIC 211

16 ASIA-PACIFIC VACCINES MARKET: COMPANY LANDSCAPE 212

16.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 212
16.2 DISEASE SHARE ANALYSIS: PFIZER, INC. 213
16.3 COUNTRY SHARE ANALYSIS: PFIZER, INC. 214
16.4 DISEASE SHARE ANALYSIS: MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.) 215
16.5 COUNTRY SHARE ANALYSIS: MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.) 216
16.6 DISEASE SHARE ANALYSIS: GLAXOSMITHKLINE PLC 217
16.7 COUNTRY SHARE ANALYSIS: GLAXOSMITHKLINE PLC. 218
16.8 DISEASE SHARE ANALYSIS: SANOFI 219
16.9 COUNTRY SHARE ANALYSIS: SANOFI 220
16.10 DISEASE SHARE ANALYSIS: SERUM INSTITUTE OF INDIA PVT. LTD. 221
16.11 COUNTRY SHARE ANALYSIS: SERUM INSTITUTE OF INDIA PVT. LTD. 222

17 SWOT ANALYSIS 223

18 COMPANY PROFILE 224

18.1 PFIZER INC. 224
- 18.1.1 COMPANY SNAPSHOT 224
- 18.1.2 REVENUE ANALYSIS 224
- 18.1.3 PRODUCT PORTFOLIO 225
- 18.1.4 RECENT DEVELOPMENTS 225
18.2 MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.) 226
- 18.2.1 COMPANY SNAPSHOT 226
- 18.2.2 REVENUE ANALYSIS 226
- 18.2.3 COMPANY WEBSITE AND PRESS RELEASES 226
- 18.2.4 PRODUCT PORTFOLIO 227
- 18.2.5 RECENT DEVELOPMENTS 227
18.3 GLAXOSMITHKLINE PLC. 229
- 18.3.1 COMPANY SNAPSHOT 229
- 18.3.2 REVENUE ANALYSIS 229
- 18.3.3 PRODUCT PORTFOLIO 230
- 18.3.4 RECENT DEVELOPMENTS 231
18.4 SANOFI 232
- 18.4.1 COMPANY SNAPSHOT 232
- 18.4.2 REVENUE ANALYSIS 232
- 18.4.3 PRODUCT PORTFOLIO 233
- 18.4.4 RECENT DEVELOPMENTS 233
18.5 SERUM INSTITUTE OF INDIA PVT. LTD. 234
- 18.5.1 COMPANY SNAPSHOT 234
- 18.5.2 PRODUCT PORTFOLIO 234
- 18.5.3 RECENT DEVELOPMENTS 236
18.6 ABBOTT 237
- 18.6.1 COMPANY SNAPSHOT 237
- 18.6.2 REVENUE ANALYSIS 237
- 18.6.3 PRODUCT PORTFOLIO 238
- 18.6.4 RECENT DEVELOPMENTS 238
18.7 ASTRAZENECA (2022) 239
- 18.7.1 COMPANY SNAPSHOT 239
- 18.7.2 REVENUE ANALYSIS 239
- 18.7.3 PRODUCT PORTFOLIO 240
- 18.7.4 RECENT DEVELOPMENTS 240
18.8 ALK 241
- 18.8.1 COMPANY SNAPSHOT 241
- 18.8.2 REVENUE ANALYSIS 241
- 18.8.3 PRODUCT PORTFOLIO 242
- 18.8.4 RECENT DEVELOPMENTS 242
18.9 BAXTER VACCINES (A SUBSIDIARY OF BAXTER) 243
- 18.9.1 COMPANY SNAPSHOT 243
- 18.9.2 REVENUE ANALYSIS 243
- 18.9.3 PRODUCT PORTFOLIO 244
- 18.9.4 RECENT DEVELOPMENT 244
18.10 BHARAT BIOTECH 245
- 18.10.1 COMPANY SNAPSHOT 245
- 18.10.2 PRODUCT PORTFOLIO 245
- 18.10.3 RECENT DEVELOPMENTS 246

18.11 BIO FARMA 247
- 18.11.1 COMPANY SNAPSHOT 247
- 18.11.2 PRODUCT PORTFOLIO 247
- 18.11.3 RECENT DEVELOPMENTS 248
18.12 BIOLOGICAL E LIMITED 249
- 18.12.1 COMPANY SNAPSHOT 249
- 18.12.2 PRODUCT PORTFOLIO 249
- 18.12.3 RECENT DEVELOPMENTS 250
18.13 DAIICHI SANKYO COMPANY, LIMITED 251
- 18.13.1 COMPANY SNAPSHOT 251
- 18.13.2 REVENUE ANALYSIS 251
- 18.13.3 PRODUCT PORTFOLIO 252
- 18.13.4 RECENT DEVELOPMENTS 252
18.14 F. HOFFMANN-LA ROCHE LTD 253
- 18.14.1 COMPANY SNAPSHOT 253
- 18.14.2 REVENUE ANALYSIS 253
- 18.14.3 PRODUCT PORTFOLIO 254
- 18.14.4 RECENT DEVELOPMENT 254
18.15 JANSSEN GLOBAL SERVICES, LLC (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.) 255
- 18.15.1 COMPANY SNAPSHOT 255
- 18.15.2 REVENUE ANALYSIS 255
- 18.15.3 PRODUCT PORTFOLIO 256
- 18.15.4 RECENT DEVELOPMENTS 256
18.16 LANZHOU BIOLOGICAL PRODUCTS RESEARCH INSTITUTE CO., LTD., 257
- 18.16.1 COMPANY SNAPSHOT 257
- 18.16.2 PRODUCT PORTFOLIO 257
- 18.16.3 RECENT DEVELOPMENTS 257
18.17 PANACEA BIOTEC LTD 258
- 18.17.1 COMPANY SNAPSHOT 258
- 18.17.2 REVENUE ANALYSIS 258
- 18.17.3 PRODUCT PORTFOLIO 259
- 18.17.4 RECENT DEVELOPMENTS 259
18.18 SEQIRUS (A SUBSIDIARY OF CSL LIMITED) 260
- 18.18.1 COMPANY SNAPSHOT 260
- 18.18.2 REVENUE ANALYSIS 260
- 18.18.3 PRODUCT PORTFOLIO 261
- 18.18.4 RECENT DEVELOPMENTS 261
18.19 TAKEDA PHARMACEUTICAL COMPANY LIMITED 262
- 18.19.1 COMPANY SNAPSHOT 262
- 18.19.2 REVENUE ANALYSIS 262
- 18.19.3 COMPANY WEBSITE AND PRESS RELEASES 263
- 18.19.4 PRODUCT PORTFOLIO 263
- 18.19.5 RECENT DEVELOPMENTS 263

19 QUESTIONNAIRE 264

20 RELATED REPORTS 268

LIST OF TABLES

TABLE 1 ASIA-PACIFIC VACCINES MARKET, PIPELINE ANALYSIS 50
TABLE 2 RECOMMENDED TEMPERATURE AND STORAGE LENGTH AT VARIOUS LEVELS OF THE COLD CHAIN. 57
TABLE 3 LOGISTICS PROCESS ACROSS DIFFERENT REGIONS. 59
TABLE 4 LAWS AND REGULATIONS IN TAIWAN 67
TABLE 5 VACCINES UNDER CLINICAL TRIAL 75
TABLE 6 THE SIDE EFFECTS RELATED TO THE VACCINES 78
TABLE 7 ASIA-PACIFIC VACCINES MARKET, BY COMPOSITION, 2021-2030 (USD MILLION) 83
TABLE 8 ASIA-PACIFIC VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 88
TABLE 9 ASIA-PACIFIC SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 89
TABLE 10 ASIA-PACIFIC LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 91
TABLE 11 ASIA-PACIFIC INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 92
TABLE 12 ASIA-PACIFIC TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 93
TABLE 13 ASIA-PACIFIC VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION) 98
TABLE 14 ASIA-PACIFIC ROUTINE VACCINES IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION) 99
TABLE 15 ASIA-PACIFIC RECOMMENDED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION) 101
TABLE 16 ASIA-PACIFIC REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION) 102
TABLE 17 ASIA-PACIFIC VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION) 107
TABLE 18 ASIA-PACIFIC PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION) 108
TABLE 19 ASIA-PACIFIC ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION) 110
TABLE 20 ASIA-PACIFIC VACCINES MARKET, BY DISEASE, 2021-2030 (USD MILLION) 115
TABLE 21 ASIA-PACIFIC VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION) 124
TABLE 22 ASIA-PACIFIC INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION) 125
TABLE 23 ASIA-PACIFIC VACCINES MARKET, BY END USER, 2022-2030 (USD MILLION) 130
TABLE 24 ASIA-PACIFIC VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 136
TABLE 25 ASIA-PACIFIC KNEE CARTILAGE REPAIR MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 143
TABLE 26 JAPAN VACCINES MARKET, BY COMPOSITION, 2021-2030 (USD MILLION) 144
TABLE 27 JAPAN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 144
TABLE 28 JAPAN SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 144
TABLE 29 JAPAN LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 145
TABLE 30 JAPAN INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 145
TABLE 31 JAPAN TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 145
TABLE 32 JAPAN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION) 146
TABLE 33 JAPAN ROUTINE VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION) 146
TABLE 34 JAPAN RECOMMENDED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION) 146
TABLE 35 JAPAN REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION) 147
TABLE 36 JAPAN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION) 147
TABLE 37 JAPAN PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION) 147
TABLE 38 JAPAN ADULT IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION) 148
TABLE 39 JAPAN VACCINES MARKET, BY DISEASE, 2021-2030 (USD MILLION) 148
TABLE 40 JAPAN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 149
TABLE 41 JAPAN INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 149
TABLE 42 JAPAN VACCINES MARKET, BY END USER, 2021-2030 (USD MILLION) 149
TABLE 43 JAPAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 149
TABLE 44 CHINA VACCINES MARKET, BY COMPOSITION, 2021-2030 (USD MILLION) 150
TABLE 45 CHINA VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 150
TABLE 46 CHINA SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 150
TABLE 47 CHINA LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 151
TABLE 48 CHINA INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 151
TABLE 49 CHINA TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 151
TABLE 50 CHINA VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION) 152
TABLE 51 CHINA ROUTINE VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION) 152
TABLE 52 CHINA RECOMMENDED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION) 152
TABLE 53 CHINA REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION) 153
TABLE 54 CHINA VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION) 153
TABLE 55 CHINA PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION) 153
TABLE 56 CHINA ADULT IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION) 154
TABLE 57 CHINA VACCINES MARKET, BY DISEASE, 2021-2030 (USD MILLION) 154
TABLE 58 CHINA VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 155
TABLE 59 CHINA INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 155
TABLE 60 CHINA VACCINES MARKET, BY END USER, 2021-2030 (USD MILLION) 155
TABLE 61 CHINA VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 155
TABLE 62 AUSTRALIA VACCINES MARKET, BY COMPOSITION, 2021-2030 (USD MILLION) 156
TABLE 63 AUSTRALIA VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 156
TABLE 64 AUSTRALIA SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 156
TABLE 65 AUSTRALIA LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 157
TABLE 66 AUSTRALIA INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 157
TABLE 67 AUSTRALIA TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 157
TABLE 68 AUSTRALIA VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION) 158
TABLE 69 AUSTRALIA ROUTINE VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION) 158
TABLE 70 AUSTRALIA RECOMMENDED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION) 158
TABLE 71 AUSTRALIA REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION) 159
TABLE 72 AUSTRALIA VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION) 159
TABLE 73 AUSTRALIA PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION) 159
TABLE 74 AUSTRALIA ADULT IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION) 160
TABLE 75 AUSTRALIA VACCINES MARKET, BY DISEASE, 2021-2030 (USD MILLION) 160
TABLE 76 AUSTRALIA VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 161
TABLE 77 AUSTRALIA INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 161
TABLE 78 AUSTRALIA VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 161
TABLE 79 INDIA VACCINES MARKET, BY COMPOSITION, 2021-2030 (USD MILLION) 162
TABLE 80 INDIA VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 162
TABLE 81 INDIA SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 162
TABLE 82 INDIA LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 163
TABLE 83 INDIA INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 163
TABLE 84 INDIA TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 163
TABLE 85 INDIA VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION) 164
TABLE 86 INDIA ROUTINE VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION) 164
TABLE 87 INDIA RECOMMENDED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION) 164
TABLE 88 INDIA REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION) 165
TABLE 89 INDIA VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION) 165
TABLE 90 INDIA PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION) 165
TABLE 91 INDIA ADULT IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION) 166
TABLE 92 INDIA VACCINES MARKET, BY DISEASE, 2021-2030 (USD MILLION) 166
TABLE 93 INDIA VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 167
TABLE 94 INDIA INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 167
TABLE 95 INDIA VACCINES MARKET, BY END USER, 2021-2030 (USD MILLION) 167
TABLE 96 INDIA VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 167
TABLE 97 SOUTH KOREA VACCINES MARKET, BY COMPOSITION, 2021-2030 (USD MILLION) 168
TABLE 98 SOUTH KOREA VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 168
TABLE 99 SOUTH KOREA SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 168
TABLE 100 SOUTH KOREA LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 169
TABLE 101 SOUTH KOREA INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 169
TABLE 102 SOUTH KOREA VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION) 170
TABLE 103 SOUTH KOREA ROUTINE VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION) 170
TABLE 104 SOUTH KOREA RECOMMENDED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION) 171
TABLE 105 SOUTH KOREA REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION) 171
TABLE 106 SOUTH KOREA VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION) 171
TABLE 107 SOUTH KOREA PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION) 172
TABLE 108 SOUTH KOREA ADULT IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION) 172
TABLE 109 SOUTH KOREA VACCINES MARKET, BY DISEASE, 2021-2030 (USD MILLION) 173
TABLE 110 SOUTH KOREA VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 173
TABLE 111 SOUTH KOREA INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 173
TABLE 112 SOUTH KOREA VACCINES MARKET, BY END USER, 2021-2030 (USD MILLION) 174
TABLE 113 SOUTH KOREA VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 174
TABLE 114 SINGAPORE VACCINES MARKET, BY COMPOSITION, 2021-2030 (USD MILLION) 175
TABLE 115 SINGAPORE SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 175
TABLE 116 SINGAPORE LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 176
TABLE 117 SINGAPORE INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 176
TABLE 118 SINGAPORE TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 176
TABLE 119 SINGAPORE VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION) 177
TABLE 120 SINGAPORE ROUTINE VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION) 177
TABLE 121 SINGAPORE RECOMMENDED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION) 177
TABLE 122 SINGAPORE REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION) 178
TABLE 123 SINGAPORE VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION) 178
TABLE 124 SINGAPORE PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION) 178
TABLE 125 SINGAPORE ADULT IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION) 179
TABLE 126 SINGAPORE VACCINES MARKET, BY DISEASE, 2021-2030 (USD MILLION) 179
TABLE 127 SINGAPORE VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 180
TABLE 128 SINGAPORE INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 180
TABLE 129 SINGAPORE VACCINES MARKET, BY END USER, 2021-2030 (USD MILLION) 180
TABLE 130 SINGAPORE VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 180
TABLE 131 MALAYSIA VACCINES MARKET, BY COMPOSITION, 2021-2030 (USD MILLION) 181
TABLE 132 MALAYSIA VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 181
TABLE 133 MALAYSIA SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 181
TABLE 134 MALAYSIA LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 182
TABLE 135 MALAYSIA INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 182
TABLE 136 MALAYSIA TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 182
TABLE 137 MALAYSIA VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION) 183
TABLE 138 MALAYSIA ROUTINE VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION) 183
TABLE 139 MALAYSIA RECOMMENDED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION) 183
TABLE 140 MALAYSIA REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION) 184
TABLE 141 MALAYSIA VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION) 184
TABLE 142 MALAYSIA PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION) 184
TABLE 143 MALAYSIA ADULT IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION) 185
TABLE 144 MALAYSIA VACCINES MARKET, BY DISEASE, 2021-2030 (USD MILLION) 185
TABLE 145 MALAYSIA VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 186
TABLE 146 MALAYSIA INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 186
TABLE 147 MALAYSIA VACCINES MARKET, BY END USER, 2021-2030 (USD MILLION) 186
TABLE 148 MALAYSIA VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 186
TABLE 149 THAILAND VACCINES MARKET, BY COMPOSITION, 2021-2030 (USD MILLION) 187
TABLE 150 THAILAND VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 187
TABLE 151 THAILAND SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 187
TABLE 152 THAILAND LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 188
TABLE 153 THAILAND INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 188
TABLE 154 THAILAND TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 188
TABLE 155 THAILAND VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION) 189
TABLE 156 THAILAND RECOMMENDED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION) 189
TABLE 157 THAILAND REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION) 190
TABLE 158 THAILAND VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION) 190
TABLE 159 THAILAND PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION) 190
TABLE 160 THAILAND ADULT IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION) 191
TABLE 161 THAILAND VACCINES MARKET, BY DISEASE, 2021-2030 (USD MILLION) 191
TABLE 162 THAILAND VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 192
TABLE 163 THAILAND INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 192
TABLE 164 THAILAND VACCINES MARKET, BY END USER, 2021-2030 (USD MILLION) 192
TABLE 165 THAILAND VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 192
TABLE 166 INDONESIA VACCINES MARKET, BY COMPOSITION, 2021-2030 (USD MILLION) 193
TABLE 167 INDONESIA VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 193
TABLE 168 INDONESIA SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 193
TABLE 169 INDONESIA LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 194
TABLE 170 INDONESIA INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 194
TABLE 171 INDONESIA TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 194
TABLE 172 INDONESIA VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION) 195
TABLE 173 INDONESIA ROUTINE VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION) 195
TABLE 174 INDONESIA RECOMMENDED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION) 195
TABLE 175 INDONESIA REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION) 196
TABLE 176 INDONESIA VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION) 196
TABLE 177 INDONESIA PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION) 196
TABLE 178 INDONESIA ADULT IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION) 197
TABLE 179 INDONESIA VACCINES MARKET, BY DISEASE, 2021-2030 (USD MILLION) 197
TABLE 180 INDONESIA VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 198
TABLE 181 INDONESIA INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 198
TABLE 182 INDONESIA VACCINES MARKET, BY END USER, 2021-2030 (USD MILLION) 198
TABLE 183 INDONESIA VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 198
TABLE 184 PHILIPPINES VACCINES MARKET, BY COMPOSITION, 2021-2030 (USD MILLION) 199
TABLE 185 PHILIPPINES VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 199
TABLE 186 PHILIPPINES SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 199
TABLE 187 PHILIPPINES LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 200
TABLE 188 PHILIPPINES INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 200
TABLE 189 PHILIPPINES TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 200
TABLE 190 PHILIPPINES VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION) 201
TABLE 191 PHILIPPINES ROUTINE VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION) 201
TABLE 192 PHILIPPINES RECOMMENDED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION) 201
TABLE 193 PHILIPPINES REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION) 202
TABLE 194 PHILIPPINES VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION) 202
TABLE 195 PHILIPPINES PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION) 202
TABLE 196 PHILIPPINES ADULT IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION) 203
TABLE 197 PHILIPPINES VACCINES MARKET, BY DISEASE, 2021-2030 (USD MILLION) 203
TABLE 198 PHILIPPINES VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 204
TABLE 199 PHILIPPINES INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 204
TABLE 200 PHILIPPINES VACCINES MARKET, BY END USER, 2021-2030 (USD MILLION) 204
TABLE 201 PHILIPPINES VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 204
TABLE 202 VIETNAM VACCINES MARKET, BY COMPOSITION, 2021-2030 (USD MILLION) 205
TABLE 203 VIETNAM VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 205
TABLE 204 VIETNAM SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 205
TABLE 205 VIETNAM LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 206
TABLE 206 VIETNAM INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 206
TABLE 207 VIETNAM TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION) 206
TABLE 208 VIETNAM VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION) 207
TABLE 209 VIETNAM ROUTINE VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION) 207
TABLE 210 VIETNAM RECOMMENDED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION) 207
TABLE 211 VIETNAM REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION) 208
TABLE 212 VIETNAM VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION) 208
TABLE 213 VIETNAM PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION) 208
TABLE 214 VIETNAM ADULT IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION) 209
TABLE 215 VIETNAM VACCINES MARKET, BY DISEASE, 2021-2030 (USD MILLION) 209
TABLE 216 VIETNAM VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 210
TABLE 217 VIETNAM INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 210
TABLE 218 VIETNAM VACCINES MARKET, BY END USER, 2021-2030 (USD MILLION) 210
TABLE 219 VIETNAM VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 210
TABLE 220 REST OF ASIA-PACIFIC VACCINES MARKET, BY COMPOSITION, 2021-2030 (USD MILLION) 211

LIST OF FIGURES

FIGURE 1 ASIA-PACIFIC VACCINES MARKET: SEGMENTATION 30
FIGURE 2 ASIA-PACIFIC VACCINES MARKET: DATA TRIANGULATION 32
FIGURE 3 ASIA-PACIFIC VACCINES MARKET: DROC ANALYSIS 33
FIGURE 4 ASIA-PACIFIC VACCINES MARKET: ASIA-PACIFIC VS COUNTRY MARKET ANALYSIS 34
FIGURE 5 ASIA-PACIFIC VACCINES MARKET: COMPANY RESEARCH ANALYSIS 34
FIGURE 6 ASIA-PACIFIC VACCINES MARKET: MULTIVARIATE MODELLING 35
FIGURE 7 ASIA-PACIFIC VACCINES MARKET: INTERVIEW DEMOGRAPHICS 37
FIGURE 8 ASIA-PACIFIC VACCINES MARKET: DBMR MARKET POSITION GRID 38
FIGURE 9 ASIA-PACIFIC VACCINES MARKET: SEGMENTATION 43
FIGURE 10 GROWING IMMUNIZATION PROGRAMS AND CAMPAIGNS AND THE HIGH PREVALENCE OF CHRONIC CONDITIONS SUCH AS FLU AND BACTERIAL INFECTIOUS DISEASES ARE DRIVING THE ASIA-PACIFIC VACCINES MARKET IN THE FORECAST PERIOD OF 2023 TO 2030 44
FIGURE 11 THE COMBINATION VACCINES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC VACCINES MARKET IN 2023 & 2030 44
FIGURE 12 FDA REGULATORY REVIEW PROCESS OF VACCINES 60
FIGURE 13 PROCESS OF SPECIAL APPROVAL ON VACCINES DURING THE 2019 H1N1PDM PANDEMIC 61
FIGURE 14 REGULATION OVERVIEW FOR THERAPEUTICS IN SINGAPORE 63
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF THE ASIA-PACIFIC VACCINES MARKET 70
FIGURE 16 ASIA-PACIFIC VACCINES MARKET: BY COMPOSITION, 2022 81
FIGURE 17 ASIA-PACIFIC VACCINES MARKET: BY COMPOSITION, 2023-2030 (USD MILLION) 82
FIGURE 18 ASIA-PACIFIC VACCINES MARKET: BY COMPOSITION, CAGR (2023-2030) 82
FIGURE 19 ASIA-PACIFIC VACCINES MARKET: BY COMPOSITION, LIFELINE CURVE 83
FIGURE 20 ASIA-PACIFIC VACCINES MARKET: BY TYPE, 2022 86
FIGURE 21 ASIA-PACIFIC VACCINES MARKET: BY TYPE, 2023-2030 (USD MILLION) 87
FIGURE 22 ASIA-PACIFIC VACCINES MARKET: BY TYPE, CAGR (2023-2030) 87
FIGURE 23 ASIA-PACIFIC VACCINES MARKET: BY TYPE, LIFELINE CURVE 88
FIGURE 24 ASIA-PACIFIC VACCINES MARKET: BY KIND, 2022 96
FIGURE 25 ASIA-PACIFIC VACCINES MARKET: BY KIND, 2023-2030 (USD MILLION) 97
FIGURE 26 ASIA-PACIFIC VACCINES MARKET: BY KIND, CAGR (2023-2030) 97
FIGURE 27 ASIA-PACIFIC VACCINES MARKET: BY KIND, LIFELINE CURVE 98
FIGURE 28 ASIA-PACIFIC VACCINES MARKET: BY AGE OF ADMINISTRATION, 2022 105
FIGURE 29 ASIA-PACIFIC VACCINES MARKET: BY AGE OF ADMINISTRATION, 2023-2030 (USD MILLION) 106
FIGURE 30 ASIA-PACIFIC VACCINES MARKET: BY AGE OF ADMINISTRATION, CAGR (2023-2030) 106
FIGURE 31 ASIA-PACIFIC VACCINES MARKET: BY AGE OF ADMINISTRATION, LIFELINE CURVE 107
FIGURE 32 ASIA-PACIFIC VACCINES MARKET: BY DISEASES, 2022 113
FIGURE 33 ASIA-PACIFIC VACCINES MARKET: BY DISEASES, 2023-2030 (USD MILLION) 114
FIGURE 34 ASIA-PACIFIC VACCINES MARKET: BY DISEASES, CAGR (2023-2030) 114
FIGURE 35 ASIA-PACIFIC VACCINES MARKET: BY DISEASES, LIFELINE CURVE 115
FIGURE 36 ASIA-PACIFIC VACCINES MARKET: BY ROUTE OF ADMINISTRATION, 2022 122
FIGURE 37 ASIA-PACIFIC VACCINES MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION) 123
FIGURE 38 ASIA-PACIFIC VACCINES MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030) 123
FIGURE 39 ASIA-PACIFIC VACCINES MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 124
FIGURE 40 ASIA-PACIFIC VACCINES MARKET: BY END USER, 2022 128
FIGURE 41 ASIA-PACIFIC VACCINES MARKET: BY END USER, 2023-2030 (USD MILLION) 129
FIGURE 42 ASIA-PACIFIC VACCINES MARKET: BY END USER, CAGR (2023-2030) 129
FIGURE 43 ASIA-PACIFIC VACCINES MARKET: BY END USER, LIFELINE CURVE 130
FIGURE 44 ASIA-PACIFIC VACCINES MARKET: BY DISTRIBUTION CHANNEL, 2022 134
FIGURE 45 ASIA-PACIFIC VACCINES MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 135
FIGURE 46 ASIA-PACIFIC VACCINES MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 135
FIGURE 47 ASIA-PACIFIC VACCINES MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 136
FIGURE 48 ASIA-PACIFIC VACCINE MARKET: SNAPSHOT (2022) 139
FIGURE 49 ASIA-PACIFIC VACCINE MARKET: BY COUNTRY (2022) 141
FIGURE 50 ASIA-PACIFIC VACCINE MARKET: BY COUNTRY (2023 & 2030) 141
FIGURE 51 ASIA-PACIFIC VACCINE MARKET: BY COUNTRY (2022 & 2030) 142
FIGURE 52 ASIA-PACIFIC VACCINE MARKET: BY COMPOSITION (2023-2030) 142
FIGURE 53 ASIA-PACIFIC VACCINES MARKET: COMPANY SHARE 2022 (%) 212
FIGURE 54 PFIZER, INC., ASIA-PACIFIC VACCINES MARKET: DISEASE SHARE 2022 (%) 213
FIGURE 55 PFIZER, INC., ASIA-PACIFIC VACCINES MARKET: COUNTRY SHARE 2022 (%) 214
FIGURE 56 MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.) ASIA-PACIFIC VACCINES MARKET: DISEASE SHARE 2022 (%) 215
FIGURE 57 MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.) ASIA-PACIFIC VACCINES MARKET: COUNTRY SHARE 2022 (%) 216
FIGURE 58 GLAXOSMITHKLINE PLC, ASIA-PACIFIC VACCINES MARKET: DISEASE SHARE 2022 (%) 217
FIGURE 59 GLAXOSMITHKLINE PLC, ASIA-PACIFIC VACCINES MARKET: COMPANY SHARE 2022 (%) 218
FIGURE 60 SANOFI, ASIA-PACIFIC VACCINES MARKET: DISEASE SHARE 2022 (%) 219
FIGURE 61 SANOFI ASIA-PACIFIC VACCINES MARKET: COUNTRY SHARE 2022 (%) 220
FIGURE 62 SERUM INSTITUTE OF INDIA PVT. LTD., ASIA-PACIFIC VACCINES MARKET: DISEASE SHARE 2022 (%) 221
FIGURE 63 SERUM INSTITUTE OF INDIA PVT. LTD. ASIA-PACIFIC VACCINES MARKET: COUNTRY SHARE 2022 (%) 222